2024-03-28T11:11:16Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00019480
2022-12-15T03:50:23Z
453:456
471:537:538:1152
2) 甲状腺の自己免疫疾患 : バセドウ病を中心に(シンポジウム 自己免疫疾患の新しい病態, 第487回新潟医学会)
2) 甲状腺の自己免疫疾患 : バセドウ病を中心に(シンポジウム 自己免疫疾患の新しい病態, 第487回新潟医学会)
Autoimmune Thyroid Disease : Especially Graves' Disease (Recent Progress in Autoimmune Diseases)
江部, 直子
谷, 長行
伊藤, 正毅
Graves' disease
auto antibody
バセドウ病
自己抗体
To elucidate the clinical significance of autoantibodies found in Graves' disease, 56 patients with Graves' disease diagnosed between 1986 and 1990 were retrospectively studied. (1) Before medical treatment, 89.1% of patients had TSH binding inhibiting immunoglobulin (TBII), 72.7% had thyroid stimulating antibody (TSAb), 76.7% had antithyroidal microsomal antibody (MCHA) and 18.2% had antithyroglobulin antibody (TGHA). (2) Positive correlation was not found between level of TSAb and free thyroxin (FT_4) concentration, but between level of TBII and FT_4 concentration. (3) The efficacy of antithyroid drugs and the prognosis were not related to the TBII, TSAb and MCHA levels respectively. (4) 68.8% of patients negative for TBII and 72.7% of patients negative for TSAb were non-suppressible by T_3 supression test after long term (more than 1 year) maintenance therapy of anti thyroid drugs. In conclusion, the measurement of TBII and TSAb seems to be useful for diagnosis of Graves' disease, but not for the prediction of the clinical course or prognosis by medical therapy.
新潟医学会
1994-03
jpn
departmental bulletin paper
http://hdl.handle.net/10191/38103
https://niigata-u.repo.nii.ac.jp/records/19480
AN00182415
00290440
新潟医学会雑誌
新潟医学会雑誌
108
3
178
184
https://niigata-u.repo.nii.ac.jp/record/19480/files/108(3)_178-184.pdf
application/pdf
1.4 MB
2019-08-08